Dosentrx is a healthcare technology company focused on what happens after therapy begins. Through the ReX® Therapy Intelligence Platform, we connect medication-taking behavior, patient experience, and timely intervention to help patients get more from their treatment.
Patients experience therapy one day at a time, but the healthcare organizations supporting them often lack visibility into what is happening between prescription and outcome.
Dosentrx exists to close that gap. By making real-world therapy behavior and patient experience visible, we help healthcare stakeholders identify risk earlier, provide more targeted support, and better understand how therapies perform.
We envision a future where every patient is supported by the visibility, intelligence, and coordinated action needed to realize the full potential of therapy.
Dosentrx brings together experience across healthcare, pharmacy operations, medical device engineering, product development, data, and life sciences. Working across the United States and Israel, our team shares a commitment to solving complex healthcare challenges and improving the experience of patients throughout therapy.
An inventor entrepreneur who holds over 20 patents, Alan invented, designed, and developed the ReX platform. Alan also developed a medical device business which was sold to Baxter.
Veteran entrepreneur and founder of ThreeWire, a pharmaceutical services company he grew to 500 employees and sold to a leading global clinical research services firm. Previously a senior executive at Spine-Tech and Alcon.
Commercial and operational leader with more than 25 years of leadership experience, including nearly 20 years in pharma services. He has a proven track record of building high-performing teams, scaling organizations, and driving growth across complex healthcare and life-science environments.
Liron brings legal and financial expertise, having trained at The Hebrew University of Jerusalem and earned an MBA in Finance. She supports female entrepreneurs through Yazamiyot and serves as an Independent Director at Moriah Jerusalem Development Corporation, overseeing a budget of NIS2.4 billion annually.
Software development leader with more than 25 years in the industry, having worked his way up from developer to VP of R&D. Now in his third VP R&D role, he specializes in building and maturing engineering teams. He joined Dosentrx believing the company can become the standard of care for solid drug treatment.
Analytics leader with more than 20 years directing real-world evidence teams at companies including Optum and OM1. At Dosentrx he applies that outcomes research experience to a new class of adherence and ePRO data, deepening research pipelines with specialty pharmacies and building partnerships with leading pharmaceutical companies.
Whether you represent a pharmaceutical manufacturer, specialty pharmacy, clinical trial sponsor, or payer, we would welcome the opportunity to understand your challenges and explore what greater therapy visibility could make possible.